A new approach to kidney transplants would reprogram the immune system - Leaps

Talaris Therapeutics, Inc., a biotech company based in Louisville, Ky., is edging closer to eradicating the need for immunosuppressive drugs for kidney transplant patients. In a series of research trials, Talaris is infusing patients with immune system stem c…

Talaris is now moving into the final clinical trial, phase III, before submitting for FDA approval. Known as Freedom-1, this trial has 17 sites open throughout the U.S., and Talaris will enroll a tot… [+7813 chars]

full article...